GlobeNewswire

Presagis Releases New Versions of its Products VAPS XT 4.2, UA Accelerator 3.0, and UA Emulator 3.0

Share

These new versions strengthen its suite of proven software solutions for developing certifiable graphical user interfaces.

MONTREAL, June 04, 2018 (GLOBE NEWSWIRE) -- Presagis, a leading provider of modeling, simulation, and user interface development software, today announced the release of new versions of its software:

These new versions further enhance an open and extensible COTS graphical HMI modeling and development software suite of solutions for developing real-time applications supporting standard and ARINC 661 certifiable and non-certifiable safety-critical environments. Presagis has provided HMI graphical modeling and development tools to produce state-of-the-art graphics and highly optimized code for both PC and embedded systems for over 30 years.

Presagis' VAPS XT is an easy-to-use yet powerful full-featured software tool for the rapid development of interactive graphical HMI displays for avionics and other applications. It allows a user to capture the design of an HMI, automatically generate source code to implement that design, and ultimately achieve certification to the highest levels of DO-178C. UA Accelerator and UA Emulator complement VAPS XT when designing an ARINC 661 System, linking graphics layout development with development of the UA system model and providing analysis of ARINC 661 Protocol.

VAPS XT 4.2

VAPS XT 4.2 is a major release providing new video support and font management capabilities as well as other functionality so developers can efficiently create more modern and advanced user interfaces with less risk. VAPS XT 4.2 offers:

  • Improvements in the areas of text handling and high quality font rendering for HD displays and embedded platforms.
  • Live video support with flexible configuration of a variety of different video sources, together with replication and scaling having low resource impact, alpha blending and chroma key support.
  • Improved Editor features to streamline editing processes and improve usability.
  • ARINC 661 support including Supplement 6 GestureArea and TouchArea widgets.

"We are very proud of these new releases because they bring our suite of products to the next level. We have added new features to VAPS XT to solidify its position as the preferred choice of developers looking to create modern, real-time, interactive graphical HMI displays," said Paul Jennings, Head of Embedded Graphics Operations at Presagis.

ARINC 661 Tools

In addition, Presagis continues to advance its product offer for the ARINC 661 development market with the release of new versions of its UA Accelerator and UA Emulator products; these products are an integral part of Presagis' ARINC 661 Development Suite providing a complete ARINC 661 systems development environment for UA and CDS development. "Providing a complete and integrated ARINC 661 development suite for cost-effective and risk-free development of CDS and UA applications has always been our goal. Release 3.0 of UA Accelerator in conjunction with VAPS XT 661 positions us as the leading provider of ARINC 661 development tools for all phases of development of avionics systems," said Matt Jackson, Technical Product Manager of Embedded Graphics at Presagis.

About Presagis

Presagis is a global leader providing commercial modeling, simulation and user interface development solutions to the aerospace, defense and security, and critical infrastructure markets. Presagis combines an open simulation development framework with expert professional services to help customers streamline development workflows, reduce project risks, and deliver game-quality immersive simulations. Presagis is also at the forefront of avionics software design for certifiable cockpit displays. The company serves hundreds of customers worldwide, including many of the world's most respected organizations such as Boeing, Lockheed Martin, Airbus, BAE Systems, and CAE. For more information, visit www.presagis.com.

For more information contact:

Carlos Carpio
Presagis
Marketing Manager, Embedded Graphics
carlos.carpio@presagis.com 
514.341.3874 ext. 4374




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Presagis via Globenewswire

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

AMG Advanced Metallurgical Group N.V. Announces Weekly Share Repurchase Program Transaction Details19.7.2019 21:00:00 CESTPress release

Amsterdam, 19 July 2019 --- AMG Advanced Metallurgical Group N.V. ("AMG", EURONEXT AMSTERDAM: "AMG") reports the repurchases made under its share repurchase program announced on 8 April 2019 and effective from 9 April 2019. Information regarding the progress of the share repurchase program and the aggregate of the transactions (calculated on a daily basis) for the period 15 July 2019 through 19 July 2019 can be found in the bottom half of the table below. Further detailed information regarding both the progress of the share repurchase program and the overall trades made on a daily basis can be accessed via the Investors section of the Company’s website, or clicking the following link: https://amg-nv.com/investors/share-buyback/ Share Repurchase Program Overall progress Share Repurchase Program: Total Repurchase Amount in Shares 2,915,630 Cumulative Repurchase Amount EUR 63,511,098 Cumulative Quantity Repurchased 2,534,054 Cumulative Average Repurchase Price EUR 25.06 Start Date 9 April

Ossur Hf : Össur acquires College Park Industries19.7.2019 17:00:00 CESTPress release

Reykjavik, 19 July 2019 Össur has signed an agreement to acquire College Park Industries, a global provider of lower and upper limb prostheses and supporting services. College Park has over 140 employees and is headquartered in Detroit, USA. Total sales amounted to USD 22 million in 2018. College Park will largely remain independent and continue to diligently serve its customer base, while allowing the combined entity to achieve strategic efficiencies. Össur is committed to growing the College Park brand over the coming years both in the United States and international markets. Together, both companies will be well-positioned to enhance their offerings in both lower and upper limb prosthetics. With this acquisition, Össur hopes to support College Park’s focus on the lower active population and further strengthen its established presence in the upper limb arena. Mutual access to technology and products will enable a more comprehensive product and service offering to customers around the

Norsk Hydro: PÅMINNELSE: Invitasjon - Presentasjon av Hydros resultat for andre kvartal 201919.7.2019 14:43:00 CESTPressemelding

Hydros resultat for andre kvartal 2019 blir offentliggjort tirsdag 23. juli 2019 kl. 07.00. Kvartalsrapporten og presentasjonsmaterialet blir samtidig gjort tilgjengelig på www.hydro.com. Presentasjon i Oslo Det blir holdt en kombinert analytikerpresentasjon og pressekonferanse ved Hydros hovedkontor i Drammensveien 260, Oslo, samme dag, kl. 08.30. Resultatet blir presentert av konsernsjef Hilde Merete Aasheim og konserndirektør for Økonomi og finans Eivind Kallevik. Hele presentasjonen kan sees direkte på web-TV. For påmelding, vennligst send mail til ir@hydro.com. I tillegg til web-TV, hvor det vil være mulig å stille spørsmål skriftlig, vil det også være mulig å ringe inn (ikke mulig å stille spørsmål over telefon). Du melder deg på denne telefonkonferansen ved å ringe: Norge +47 2100 2610 UK +44 (0)330 336 9125 USA +1 929-477-0324 Sverige +46 (0)8 5033 6574 Brasil +55 11 3181 5427 Tyskland +49 (0)89 20303 5709 Kode: 3104804 Q&A / Telefonkonferanse Det blir holdt en telefonkonferans

Norsk Hydro: REMINDER: Invitation - Hydro’s second quarter results 201919.7.2019 14:43:00 CESTPress release

Hydro's second quarter results 2019 will be released at 07:00 CEST (01:00 AM EDT, 06:00 UK time), on Tuesday July 23, 2019. The quarterly report and presentation slides will be available on www.hydro.com at the same time. Presentation in Oslo Hydro will host a combined analyst and press conference, in English, at its corporate headquarters at Drammensveien 260, Oslo, at 08:30 CEST the same day. The presentation will be held by President and CEO Hilde Merete Aasheim and CFO Eivind Kallevik and can also be seen on web TV. To attend the presentation in Oslo, please register by sending a mail to ir@hydro.com. In addition to the webcast, where it will be possible to ask questions in writing, it will also be possible to dial in (not possible to ask questions over the phone). Dial-in numbers for this conference call are: Norway +47 2100 2610 UK +44 (0)330 336 9125 USA +1 929-477-0324 Sweden +46 (0)8 5033 6574 Brazil +55 11 3181 5427 Germany +49 (0)89 20303 5709 Confirmation Code: 3104804 Q&A

Sunstone Life Science Ventures invests in Karolinska Development's portfolio company Forendo Pharma19.7.2019 14:00:00 CESTPressemelding

STOCKHOLM – July 19, 2019. Karolinska Development's portfolio company Forendo Pharma announces today that Sunstone Life Science Ventures joins the existing international investor syndicate and has made a EUR 5 million investment in Forendo Pharma. Claus Andersson, General Partner from Sunstone, joins Forendo Pharma’s Board of Directors. With the investment, Sunstone joins the existing international investor syndicate comprising Novo Seeds, Karolinska Development, Innovestor, Novartis Venture Fund, M Ventures and Vesalius Biocapital Partners. The new financing will enable Forendo Pharma to progress its lead endometriosis program, FOR-6219, an HSD17B1 enzyme inhibitor, into the next phase of clinical studies after the successful completion of its Phase 1a study earlier this year. Endometriosis is a chronic condition that affects many women of reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available treatments for endometriosis have